
Opinion|Videos|May 2, 2024
Unmet Needs and Clinical Data with Hepatic Artery Infusion in Intrahepatic Cholangiocarcinoma
Drs Connell and Merkow discuss the current treatment landscape in intrahepatic cholangiocarcinoma and review recent clinical data in that space.
Advertisement
Episodes in this series

Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in NSCLC, HER2+ gastroesophageal cancer, low-grade glioma, HR+ breast cancer, and CML.

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA granted priority review to sonesitatug vedotin for previously treated CLDN18.2-positive advanced gastroesophageal cancers.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
The OncFive: Top Oncology Articles for the Week of 11/15
3
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
4
Dr Leighl on HARMONi Survival Data and the FDA's Decision on Ivonescimab in Previously Treated EGFR-Mutated NSCLC
5


